RS67399B1 - Jedinjenja modulatori gpr52 - Google Patents

Jedinjenja modulatori gpr52

Info

Publication number
RS67399B1
RS67399B1 RS20251139A RSP20251139A RS67399B1 RS 67399 B1 RS67399 B1 RS 67399B1 RS 20251139 A RS20251139 A RS 20251139A RS P20251139 A RSP20251139 A RS P20251139A RS 67399 B1 RS67399 B1 RS 67399B1
Authority
RS
Serbia
Prior art keywords
disorder
disorders
compound
optionally substituted
salt
Prior art date
Application number
RS20251139A
Other languages
English (en)
Serbian (sr)
Inventor
Stephen Paul Watson
Nigel Alan Swain
Michael Alistair O'brien
Original Assignee
Nxera Pharma Uk Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nxera Pharma Uk Ltd filed Critical Nxera Pharma Uk Ltd
Publication of RS67399B1 publication Critical patent/RS67399B1/sr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/661Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/675Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
RS20251139A 2021-09-15 2022-09-15 Jedinjenja modulatori gpr52 RS67399B1 (sr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB2113186.7A GB202113186D0 (en) 2021-09-15 2021-09-15 GPR52 Modulator compounds
EP22778038.4A EP4401833B1 (en) 2021-09-15 2022-09-15 Gpr52 modulator compounds
PCT/GB2022/052328 WO2023041909A1 (en) 2021-09-15 2022-09-15 Gpr52 modulator compounds

Publications (1)

Publication Number Publication Date
RS67399B1 true RS67399B1 (sr) 2025-11-28

Family

ID=78149263

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20251139A RS67399B1 (sr) 2021-09-15 2022-09-15 Jedinjenja modulatori gpr52

Country Status (22)

Country Link
US (1) US20240376070A1 (https=)
EP (1) EP4401833B1 (https=)
JP (1) JP2024535860A (https=)
KR (1) KR20240058852A (https=)
CN (1) CN117999258A (https=)
AU (1) AU2022348201A1 (https=)
CA (1) CA3232606A1 (https=)
CL (1) CL2024000742A1 (https=)
DK (1) DK4401833T3 (https=)
ES (1) ES3053759T3 (https=)
FI (1) FI4401833T3 (https=)
GB (1) GB202113186D0 (https=)
HR (1) HRP20251420T1 (https=)
IL (1) IL311015A (https=)
LT (1) LT4401833T (https=)
MX (1) MX2024003248A (https=)
PL (1) PL4401833T3 (https=)
PT (1) PT4401833T (https=)
RS (1) RS67399B1 (https=)
SI (1) SI4401833T1 (https=)
SM (1) SMT202500449T1 (https=)
WO (1) WO2023041909A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202206413A (zh) 2020-04-22 2022-02-16 美商紐羅克里生物科學有限公司 Gpr52調節劑及其使用方法
WO2025252061A1 (zh) * 2024-06-04 2025-12-11 海思科医药集团股份有限公司 一种gpr52激动剂及其在医药上的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20180004193A (ko) 2015-04-29 2018-01-10 아레나 파마슈티칼스, 인크. Gpr52와 관련된 장애의 치료 또는 예방을 위한 gpr52 조절제로서 1-헤테로아릴-인돌린-4-카르복스아미드
JP7394747B2 (ja) * 2017-09-13 2023-12-08 ノバルティス アーゲー ジフェニル誘導体及びその使用
CA3156474A1 (en) * 2019-11-08 2021-05-14 Heptares Therapeutics Limited GPR52 MODULATING COMPOUNDS
GB202003668D0 (en) 2020-03-13 2020-04-29 Heptares Therapeutics Ltd GPR52 Modulator compounds

Also Published As

Publication number Publication date
AU2022348201A1 (en) 2024-03-28
KR20240058852A (ko) 2024-05-07
EP4401833A1 (en) 2024-07-24
LT4401833T (lt) 2025-12-10
WO2023041909A1 (en) 2023-03-23
GB202113186D0 (en) 2021-10-27
JP2024535860A (ja) 2024-10-02
FI4401833T3 (fi) 2025-11-25
SI4401833T1 (sl) 2026-01-30
EP4401833B1 (en) 2025-10-22
DK4401833T3 (da) 2025-11-17
PT4401833T (pt) 2025-11-14
CN117999258A (zh) 2024-05-07
PL4401833T3 (pl) 2026-02-16
HRP20251420T1 (hr) 2026-01-02
MX2024003248A (es) 2024-04-02
ES3053759T3 (en) 2026-01-26
CL2024000742A1 (es) 2024-09-27
IL311015A (en) 2024-04-01
US20240376070A1 (en) 2024-11-14
SMT202500449T1 (it) 2026-01-12
CA3232606A1 (en) 2023-03-23

Similar Documents

Publication Publication Date Title
EP3634956B1 (en) Aryl heterocyclic piperidinone formyl peptide 2 receptor and formyl peptide 1 receptor agonists
KR102726637B1 (ko) 6-아미노이소퀴놀린의 일가-(산) 염 및 이의 용도
EP4117784B1 (en) Gpr52 modulator compounds
CA3203285A1 (en) Heteroaryl carboxamide compound
CZ361392A3 (en) Novel azaheterocyclylmethyl-chromans
TWI770841B (zh) 作為組蛋白脫乙醯基酶6抑制劑之1,3,4-㗁二唑衍生物化合物及包含其的醫藥組合物
RS67399B1 (sr) Jedinjenja modulatori gpr52
JP2008534597A (ja) PKC−θのインヒビターとして有用なピリジン誘導体
NO309936B1 (no) 2,7-Substituerte oktahydro-pyrrol[1,2-a]pyrazin-derivater, anvendelse derav, farmasøytisk preparat, samt mellomprodukter for fremstilling av derivatene
CN116507622B (zh) Gpr52调节剂化合物
EP4129994A1 (en) Novel pyrimidine derivative, and composition for preventing or treating neurodegenerative diseases and cancer, comprising same
HK40107480B (en) Gpr52 modulator compounds
HK40107480A (en) Gpr52 modulator compounds
EP2524912A1 (en) Amine derivatives
RU2844473C1 (ru) Соединения модуляторы gpr52
EP4698515A1 (en) Carbocyclic phenylpyrrolidinone urea fpr2 agonists
HK40078521A (en) Gpr52 modulator compounds
HK40078521B (en) Gpr52 modulator compounds
HK40075698A (en) 1,3,4 oxadiazole derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same